Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1287-1289

  Alffenaar, J W C ^a   Van Der Laan, T ^b   Simons, S ^c   Van Der Werf, T S ^a   Van De Kasteele, P J ^b   De Neeling, H ^b   Van Soolingen, D ^b,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ETHAMBUTOL; ISONIAZID; LINEZOLID; PNU 100480; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ACETAMIDES; ANTITUBERCULAR AGENTS; ETHAMBUTOL; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; RIFAMPIN; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79952346767     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01297-10     Document Type: Article

References (27)

1. Alcala, L., et al. 2003. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob. Agents Chemother. 47:416-417.
2. Alffenaar, J. W. C., et al. 2010. Comparison of pharmacokinetics of two dosage regime of linezolid in MDR/XDR-TB patients. Clin. Pharmacokinet. 49:559-565.
3. Borrell, S., and S. Gagneux. 2009. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1456-1466.
4. Bressler, A. M., S. M. Zimmer, J. L. Gilmore, and J. Somani. 2004. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 4:528-531.
5. Brickner, S. J., et al. 1996. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem. 39:673-679.
6. Cohn, D. L. 1995. Treatment of multidrug-resistant tuberculosis. J. Hosp. Infect. 30(Suppl.):322-328.
7. Cynamon, M. H., S. P. Klemens, C. A. Sharpe, and S. Chase. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43:1189-1191.
8. Dave, S., et al. 2009. Comparative growth pattern of multi drug resistance versus susceptible isolates of Mycobacterium tuberculosis in mice lungs. Indian J. Med. Res. 130:58-62.
9. Fortun, J., et al. 2005. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56:180-185.
10. Geerligs, W. A., R. van Altena, W. C. M. De Lange, D. van Soolingen, and T. S. van der Werf. 2000. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int. J. Tuberc. Lung Dis. 4:758-764.
11. Gerson, S. L., et al. 2002. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 46:2723-2726.
12. Huband, M. D., C. K. Stover, E. A. Trevino, and A. W. Weissfeld. 2010. In vitro activity of PNU-100480, PNU-101603, and PNU-101244: novel oxazolidinone antibacterials versus Mycobacterium tuberculosis, abstr. F1-1512. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
13. Koh, W. J., et al. 2009. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J. Antimicrob. Chemother. 64:1119-1120.
14. Lunn, D. J., A. Thomas, N. Best, and D. Spiegelhalter. 2000. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat. Comput. 10:325-337.
15. McKee, E. E., M. Ferguson, A. T. Bentley, and T. A. Marks. 2006. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50:2042-2049.
16. Migliori, G. B., et al. 2009. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J. 34:387-393.
17. Nagiec, E. E., et al. 2005. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob. Agents Chemother. 49:3896-3902.
18. Nam, H. S., W. J. Koh, O. J. Kwon, S. N. Cho, and T. S. Shim. 2009. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int. J. Antimicrob. Agents 33:92-93.
19. Park, I. N., et al. 2006. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 58:701-704.
20. Rodriguez, J. C., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467.
21. Salomon, N., et al. 1995. Predictors and outcome of multidrug-resistant tuberculosis. Clin. Infect. Dis. 21:1245-1252.
22. Sbardella, G., et al. 2004. Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480. Bioorg. Med. Chem. Lett. 14:1537-1541.
23. Turett, G. S., et al. 1995. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin. Infect. Dis. 21:1238-1244.
24. Wallis, R. S., et al. 2010. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55:567-574.
25. Wallis, R. S., et al. 2010. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202:745-751.
26. Williams, K. N., et al. 2009. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med. 180:371-376.
27. Williams, K. N., et al. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319.